TR 396 Mouse Pathology Tables
INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)
MONOCHLOROACETIC ACID
NTP Experiment-Test: 05705-01 Report: PEIRPT05
Study Type: CHRONIC Date: 09/18/94
Route: GAVAGE Time: 19:48:26
Facility: International Research and Development Corp.
Chemical CAS #: 79-11-8
Lock Date: None
Cage Range: All
Reasons For Removal: All
Removal Date Range: All
Treatment Groups: Include All
a Number of animals examined microscopically at site and number of animals with lesion
Page 1
NTP Experiment-Test: 05705-01 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC MONOCHLOROACETIC ACID Date: 09/18/94
Route: GAVAGE Time: 19:48:26
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE CONTROL 50 MG/KG 100MG/KG
FEMALE FEMALE FEMALE
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially in Study 60 60 60
Early Deaths
Dead 9 12 9
Moribund 8 8 4
Dosing Accident 1 3
Survivors
Terminal Sacrifice 41 40 44
Dead 1
Animals Examined Microscopically 60 60 60
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Esophagus (60) (60)
Gallbladder (55) (1) (51)
Histiocytic Sarcoma 1 (2%)
Intestine Large, Cecum (52) (53)
Histiocytic Sarcoma 1 (2%)
Intestine Large, Rectum (60) (58)
Histiocytic Sarcoma 1 (2%)
Intestine Small, Ileum (52) (54)
Histiocytic Sarcoma 1 (2%)
Intestine Small, Jejunum (52) (1) (54)
Histiocytic Sarcoma 1 (2%)
Liver (60) (60) (60)
Granulosa Cell Tumor Malignant, Metastatic,
Ovary 1 (2%)
Hemangiosarcoma 1 (2%)
Hepatocellular Carcinoma 1 (2%)
Hepatocellular Adenoma 1 (2%) 1 (2%) 2 (3%)
Histiocytic Sarcoma 3 (5%) 2 (3%) 1 (2%)
Mesentery (23) (7) (16)
Histiocytic Sarcoma 2 (9%) 1 (14%) 1 (6%)
Sarcoma, Metastatic, Uterus 1 (6%)
Pancreas (60) (60)
Histiocytic Sarcoma 1 (2%)
Sarcoma, Metastatic, Uterus 1 (2%)
Salivary Glands (59) (60)
Histiocytic Sarcoma 1 (2%)
Stomach, Forestomach (60) (59) (60)
Squamous Cell Papilloma 2 (3%)
Stomach, Glandular (57) (60) (60)
Histiocytic Sarcoma 1 (2%) 1 (2%)
____________________________________________________________________________________________________________________________________
Page 2
NTP Experiment-Test: 05705-01 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC MONOCHLOROACETIC ACID Date: 09/18/94
Route: GAVAGE Time: 19:48:26
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE CONTROL 50 MG/KG 100MG/KG
FEMALE FEMALE FEMALE
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Heart (60) (60) (60)
Fibrosarcoma, Metastatic, Skin 1 (2%)
Histiocytic Sarcoma 2 (3%) 1 (2%)
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Gland, Cortex (59) (1) (60)
Histiocytic Sarcoma 1 (2%)
Subcapsular, Adenoma 1 (2%)
Adrenal Gland, Medulla (57) (59)
Pheochromocytoma Malignant 1 (2%)
Pheochromocytoma Benign 1 (2%)
Islets, Pancreatic (59) (59)
Adenoma 1 (2%)
Parathyroid Gland (34) (43)
Pituitary Gland (55) (6) (57)
Adenoma 5 (9%) 6 (100%) 7 (12%)
Pars Intermedia, Adenoma 1 (2%) 1 (2%)
Thyroid Gland (60) (1) (60)
Histiocytic Sarcoma 1 (2%)
Follicular Cell, Adenoma 1 (2%) 1 (100%) 2 (3%)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
None
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Ovary (59) (24) (60)
Adenocarcinoma, Metastatic, Uterus 1 (2%)
Adenoma, Papillary 1 (2%)
Choriocarcinoma 1 (4%)
Cystadenoma 1 (2%)
Granulosa Cell Tumor Malignant 1 (4%)
Granulosa Cell Tumor Benign 1 (2%) 1 (4%)
Histiocytic Sarcoma 2 (3%) 1 (4%)
Mixed Tumor Benign 1 (2%)
Oviduct (1)
Uterus (60) (43) (60)
Adenocarcinoma 2 (3%)
Hemangioma 1 (2%)
Histiocytic Sarcoma 1 (2%) 1 (2%)
Page 3
NTP Experiment-Test: 05705-01 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC MONOCHLOROACETIC ACID Date: 09/18/94
Route: GAVAGE Time: 19:48:26
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE CONTROL 50 MG/KG 100MG/KG
FEMALE FEMALE FEMALE
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM - cont
Leiomyosarcoma 1 (2%)
Sarcoma 1 (2%)
Endometrium, Deciduoma Benign 1 (2%)
Endometrium, Histiocytic Sarcoma 1 (2%)
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Bone Marrow (60) (21) (60)
Plasma Cell Tumor NOS 1 (2%)
Lymph Node (60) (19) (58)
Axillary, Sarcoma, Metastatic 1 (5%)
Bronchial, Histiocytic Sarcoma 1 (2%)
Iliac, Histiocytic Sarcoma 1 (2%) 1 (5%) 1 (2%)
Inguinal, Histiocytic Sarcoma 1 (2%)
Mediastinal, Fibrosarcoma, Metastatic, Skin 1 (5%)
Mediastinal, Histiocytic Sarcoma 1 (2%)
Pancreatic, Histiocytic Sarcoma 1 (5%)
Renal, Histiocytic Sarcoma 1 (5%) 1 (2%)
Lymph Node, Mesenteric (60) (12) (58)
Histiocytic Sarcoma 2 (3%) 1 (8%) 1 (2%)
Sarcoma, Metastatic, Uterus 1 (2%)
Spleen (60) (25) (60)
Histiocytic Sarcoma 1 (2%) 1 (4%) 2 (3%)
Thymus (54) (3) (53)
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Mammary Gland (59) (4) (60)
Adenocarcinoma 2 (3%) 2 (50%) 1 (2%)
Adenocarcinoma, Multiple 1 (2%)
Fibrosarcoma, Metastatic, Skin 1 (2%)
Histiocytic Sarcoma 1 (2%) 1 (2%)
Skin (60) (50) (60)
Fibrosarcoma 2 (3%) 2 (4%) 1 (2%)
Sarcoma 1 (2%)
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
Bone (60) (1) (60)
Skeletal Muscle (3) (2) (2)
Adenocarcinoma, Metastatic, Uterus 1 (50%)
Fibrosarcoma, Metastatic, Skin 1 (33%)
Sarcoma 1 (33%)
____________________________________________________________________________________________________________________________________
Page 4
NTP Experiment-Test: 05705-01 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC MONOCHLOROACETIC ACID Date: 09/18/94
Route: GAVAGE Time: 19:48:26
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE CONTROL 50 MG/KG 100MG/KG
FEMALE FEMALE FEMALE
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
Brain (60) (1) (60)
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (60) (14) (60)
Alveolar/Bronchiolar Adenoma 2 (14%) 2 (3%)
Alveolar/Bronchiolar Carcinoma 1 (7%)
Fibrosarcoma, Metastatic, Skin 1 (2%) 1 (7%)
Histiocytic Sarcoma 1 (7%) 1 (2%)
Nose (60) (60) (60)
Trachea (60) (60)
Histiocytic Sarcoma 1 (2%)
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Eye (1) (1)
Harderian Gland (1)
Adenoma 1 (100%)
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (60) (5) (60)
Adenocarcinoma, Metastatic, Uterus 1 (2%)
Histiocytic Sarcoma 1 (20%) 2 (3%)
Ureter (1) (1)
Urinary Bladder (57) (1) (56)
Histiocytic Sarcoma 1 (2%) 1 (2%)
Sarcoma, Metastatic, Uterus 1 (2%)
____________________________________________________________________________________________________________________________________
SYSTEMIC LESIONS
Multiple Organs *(60) *(60) *(60)
Histiocytic Sarcoma 3 (5%) 2 (3%) 3 (5%)
Lymphoma Malignant Lymphocytic 2 (3%) 3 (5%)
Lymphoma Malignant Mixed 27 (45%) 14 (23%) 13 (22%)
Lymphoma Malignant Undifferentiated Cell 1 (2%)
____________________________________________________________________________________________________________________________________
* Number of animals with any tissue examined microscopically
Page 5
NTP Experiment-Test: 05705-01 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC MONOCHLOROACETIC ACID Date: 09/18/94
Route: GAVAGE Time: 19:48:26
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE CONTROL 50 MG/KG 100MG/KG
FEMALE FEMALE FEMALE
____________________________________________________________________________________________________________________________________
TUMOR SUMMARY
Total Animals with Primary Neoplasms (b) 41 33 27
Total Primary Neoplasms 55 40 42
Total Animals with Benign Neoplasms 14 11 13
Total Benign Neoplasms 16 11 18
Total Animals with Malignant Neoplasms 36 27 20
Total Malignant Neoplasms 39 29 23
Total Animals with Metastatic Neoplasms 1 3 2
Total Metastatic Neoplasm 3 5 7
Total Animals with Malignant Neoplasms
Uncertain Primary Site
Total Animals with Neoplasms Uncertain-
Benign or Malignant 1
Total Uncertain Neoplasms 1
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
b Primary tumors: all tumors except metastatic tumors
Page 6
NTP Experiment-Test: 05705-01 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC MONOCHLOROACETIC ACID Date: 09/18/94
Route: GAVAGE Time: 19:48:26
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE CONTROL 50 MG/KG 100MG/KG
MALE MALE MALE
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially in Study 60 60 60
Early Deaths
Dead 7 11 26
Moribund 5 10 8
Dosing Accident 2 5
Survivors
Terminal Sacrifice 46 39 21
Animals Examined Microscopically 60 60 60
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Esophagus (59) (60) (60)
Intestine Large, Rectum (58) (58) (50)
Adenocarcinoma 1 (2%)
Intestine Small, Jejunum (53) (56) (40)
Liver (60) (59) (59)
Carcinoma, Metastatic, Uncertain Primary Site 1 (2%)
Hemangioma 2 (3%)
Hemangiosarcoma 1 (2%) 1 (2%)
Hepatocellular Carcinoma 6 (10%) 2 (3%) 5 (8%)
Hepatocellular Adenoma 6 (10%) 6 (10%) 1 (2%)
Mesentery (4) (1)
Sarcoma, Metastatic, Skin 1 (25%)
Pancreas (58) (59) (57)
Pharynx (1)
Palate, Mast Cell Tumor Malignant 1 (100%)
Stomach, Glandular (58) (59) (54)
Carcinoma, Metastatic, Uncertain Primary Site 1 (2%)
Tooth (5) (2) (2)
Peridontal Tissue, Mast Cell Tumor Malignant 1 (20%)
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Blood Vessel (58) (58) (59)
Fibrosarcoma, Metastatic, Skin 1 (2%)
Heart (60) (59) (60)
Fibrosarcoma, Metastatic, Skin 1 (2%)
Hemangioma 1 (2%)
____________________________________________________________________________________________________________________________________
Page 7
NTP Experiment-Test: 05705-01 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC MONOCHLOROACETIC ACID Date: 09/18/94
Route: GAVAGE Time: 19:48:26
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE CONTROL 50 MG/KG 100MG/KG
MALE MALE MALE
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Gland, Cortex (60) (59) (60)
Adenoma 1 (2%)
Carcinoma 1 (2%)
Subcapsular, Adenoma 2 (3%) 1 (2%) 2 (3%)
Adrenal Gland, Medulla (59) (59) (60)
Pheochromocytoma Benign 1 (2%) 1 (2%)
Thyroid Gland (60) (58) (57)
Follicular Cell, Adenoma 1 (2%)
Follicular Cell, Carcinoma 1 (2%)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
None
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Preputial Gland (8) (6) (8)
Sarcoma, Metastatic, Skin 1 (13%)
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Bone Marrow (60) (60) (60)
Lymph Node (58) (55) (51)
Mediastinal, Fibrosarcoma, Metastatic, Skin 1 (2%)
Pancreatic, Carcinoma, Metastatic, Uncertain
Primary Site 1 (2%)
Lymph Node, Mesenteric (56) (55) (50)
Hemangiosarcoma 1 (2%)
Sarcoma, Metastatic, Skin 1 (2%)
Spleen (59) (58) (60)
Hemangioma 1 (2%)
Thymus (49) (42) (38)
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Skin (60) (60) (59)
Fibrosarcoma 4 (7%) 3 (5%)
Fibrosarcoma, Multiple 1 (2%)
Neurofibrosarcoma 2 (3%)
Sarcoma 1 (2%) 1 (2%)
____________________________________________________________________________________________________________________________________
Page 8
NTP Experiment-Test: 05705-01 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC MONOCHLOROACETIC ACID Date: 09/18/94
Route: GAVAGE Time: 19:48:26
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE CONTROL 50 MG/KG 100MG/KG
MALE MALE MALE
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
Skeletal Muscle (1) (1) (1)
Fibrosarcoma, Metastatic 1 (100%)
Thoracic, Fibrosarcoma, Metastatic, Skin 1 (100%)
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
Brain (60) (58) (60)
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (60) (59) (60)
Alveolar/Bronchiolar Adenoma 6 (10%) 10 (17%) 4 (7%)
Alveolar/Bronchiolar Adenoma, Multiple 3 (5%) 1 (2%)
Alveolar/Bronchiolar Carcinoma 4 (7%)
Fibrosarcoma, Metastatic, Skin 2 (3%) 1 (2%)
Hepatocellular Carcinoma, Metastatic, Liver 2 (3%) 1 (2%)
Sarcoma, Metastatic, Uncertain Primary Site 1 (2%)
Nose (60) (59) (60)
Trachea (60) (59) (60)
Fibrosarcoma, Metastatic, Skin 2 (3%)
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Harderian Gland (3) (3) (2)
Adenoma 2 (67%) 3 (100%) 2 (100%)
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (60) (59) (60)
Sarcoma, Metastatic, Skin 1 (2%)
Urinary Bladder (57) (58) (54)
____________________________________________________________________________________________________________________________________
SYSTEMIC LESIONS
Multiple Organs *(60) *(60) *(60)
Lymphoma Malignant Mixed 8 (13%) 7 (12%) 5 (8%)
____________________________________________________________________________________________________________________________________
* Number of animals with any tissue examined microscopically
Page 9
NTP Experiment-Test: 05705-01 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC MONOCHLOROACETIC ACID Date: 09/18/94
Route: GAVAGE Time: 19:48:26
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE CONTROL 50 MG/KG 100MG/KG
MALE MALE MALE
____________________________________________________________________________________________________________________________________
TUMOR SUMMARY
Total Animals with Primary Neoplasms (b) 31 32 21
Total Primary Neoplasms 47 39 28
Total Animals with Benign Neoplasms 20 21 11
Total Benign Neoplasms 23 23 11
Total Animals with Malignant Neoplasms 20 14 13
Total Malignant Neoplasms 24 16 17
Total Animals with Metastatic Neoplasms 5 3 2
Total Metastatic Neoplasm 10 9 2
Total Animals with Malignant Neoplasms 2
Uncertain Primary Site
Total Animals with Neoplasms Uncertain-
Benign or Malignant
Total Uncertain Neoplasms
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
b Primary tumors: all tumors except metastatic tumors
Page 10
------------------------------------------------------------
---------- END OF REPORT ----------
------------------------------------------------------------